Page last updated: 2024-11-13

10-hydroxygambogic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 10-Hydroxygambogic Acid: A Promising Anti-Cancer Agent

10-Hydroxygambogic acid (10-HGA) is a natural compound extracted from the resin of the **garcinia hanburyi** tree, also known as **gamboge**. It's a **highly potent and selective anti-cancer agent** with significant potential in research.

**Here's what makes 10-HGA important for research:**

**1. Anti-Cancer Properties:**

* **Multiple Mechanisms of Action:** 10-HGA has shown remarkable activity against a wide range of cancer cell lines, including leukemia, lymphoma, lung, liver, colon, breast, and prostate cancers. It works through several pathways, including:
* **Induction of Apoptosis:** It triggers programmed cell death in cancer cells, effectively eliminating them.
* **Cell Cycle Arrest:** It inhibits the proliferation of cancer cells by halting the cell cycle at specific checkpoints.
* **Inhibition of Angiogenesis:** It prevents the formation of new blood vessels that supply nutrients to tumors, effectively starving them.
* **Anti-Metastatic Activity:** It can suppress the spread of cancer cells to other parts of the body.
* **Selectivity and Low Toxicity:** 10-HGA exhibits selective toxicity, targeting cancer cells more effectively than normal cells, thus minimizing side effects.

**2. Research Potential:**

* **Novel Drug Development:** 10-HGA is being investigated as a potential therapeutic agent for the treatment of various cancers. Researchers are actively exploring its potential to be formulated into effective and safe drug therapies.
* **Combination Therapy:** 10-HGA shows synergistic effects when combined with other anticancer agents, enhancing their efficacy and offering better therapeutic outcomes.
* **Understanding Cancer Biology:** 10-HGA's mechanisms of action provide valuable insights into the complex pathways involved in cancer development and progression. This knowledge can lead to the development of new, targeted cancer therapies.

**3. Ongoing Research:**

* **Clinical Trials:** Several clinical trials are currently underway to evaluate the safety and efficacy of 10-HGA in humans with various cancer types.
* **Preclinical Studies:** Extensive preclinical research continues to explore 10-HGA's potential as a cancer therapeutic, including its pharmacokinetics, pharmacodynamics, and potential toxicity.

**Despite its promising potential, further research is needed to fully understand 10-HGA's effects and its potential for clinical application.** However, the current research data strongly suggest that 10-HGA holds significant promise as a potential anti-cancer agent and warrants continued investigation.

10-hydroxygambogic acid: metabolite of gambogic acid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71450485
CHEMBL ID2205164
MeSH IDM0547218

Synonyms (2)

Synonym
10-hydroxygambogic acid
CHEMBL2205164
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID716719Covalent binding affinity to human recombinant TRX-1 assessed as change in protein configuration at 0.1 mM by MALDITOF mass spectrometry2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1216616Drug level in PBS buffer treated with gambogic acid at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis in absence of liver microsomes2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216628Retention time of the compound in Sprague-Dawley rat bile treated with gambogic acid at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216637Drug level in rat liver microsomes assessed as CYP450-mediated compound formation treated with gambogic acid at 50 uM preincubated for 10 mins followed by NADPH addition measured after 1 hr by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID1216638Drug level in Sprague-Dawley rat feces treated with gambogic acid at 4 mg/kg, iv measured over 24 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
AID716718Covalent binding affinity to human recombinant TRX-2 assessed as change in protein configuration at 0.05 mM by MALDITOF mass spectrometry2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain.
AID1216640Drug level in Sprague-Dawley rat plasma treated with gambogic acid at 4 mg/kg, iv measured over 4 hrs by LC-DAD-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Metabolism of gambogic acid in rats: a rare intestinal metabolic pathway responsible for its final disposition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]